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Abstract The Nef protein of HIV-1 binds to and induces
apoptotic cytolysis of uninfected but activated human peripheral
blood mononuclear cells (PBMC) and various cell line cells
derived from CD4+ T, CD8+ T and B lymphocytes, macro-
phages, and neutrophils. The Nef-induced apoptosis also occurs
with blood cells not expressing CD95 (Fas). The Nef-induced
apoptosis as well as Fas-mediated apoptosis was inhibited by
acetyl-Try-Val-Ala-Asp-CHO, an IL-1L converting enzyme
(ICE) inhibitor. On the other hand, serine/threonine protein
kinase (PK) inhibitors, H-7, fasudil hydrochloride and M3,
inhibited the Nef-induced apoptosis, and not the Fas-mediated
one, without affecting the cell-binding activity of Nef and Nef-
binding capacity of the activated cells. Preincubation of the cells
with the drugs before being bound by Nef was required for the
inhibition of apoptosis. These results suggest that the PK
inhibitors specifically act on a cellular protein involved in the
upper stream of signal transduction pathway of the Nef-induced
apoptosis, which is different from the Fas-mediated pathway but
meets it upstream of ICE. In addition, the drugs suppressed the
cellular activation-associated cell surface expression of a putative
Nef-binding protein in PBMC, although they had no influence on
its expression in cell line cells. These findings suggest the
feasibility of clinical use of the PK inhibitors to prevent the
development of AIDS by inhibiting the Nef-induced apoptosis of
uninfected blood cells.
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1. Introduction
During the subclinical stage of HIV-1 infection, a variety of
uninfected blood cells including CD4 T and CD8 T lym-
phocytes and neutrophils are destroyed more extensively
showing a rapid turnover than virus-infected CD4 T cells
and macrophages [1^3]. Extended death of the uninfected cells
should result in immune suppression leading to the develop-
ment of AIDS [4]. Inhibition of the cytolysis of uninfected
cells is therefore considered to prevent or delay the onset of
AIDS. On the other hand, it seems now established that the
Nef protein of HIV-1 contributes substantially to pathogene-
sis of AIDS, although the mechanism remains unclear. We
have shown that the Nef protein, found on the surface of
virus-infected cells [5] and in a soluble form in sera of HIV-
1-infected patients [6], binds to a broad spectrum of unin-
fected blood cells and, upon cross-linking by anti-Nef anti-
bodies, it induces apoptotic cytolysis of the cells independ-
ently of CD95 (Fas) [6^8]. Cell surface expression of a
putative Nef-binding protein, which occurs with various cell
types much broader than those expressing Fas, depends on
cellular activation [8]. On the other hand, various murine
blood cells are also competent as a target of Nef-induced
apoptosis in a similar fashion to human cells [9]. The Nef-
induced apoptosis of murine cells is speci¢cally inhibited by
serine/threonine protein kinase (PK) inhibitors not inhibiting
Fas-mediated apoptosis, suggesting that the Nef-induced
apoptosis undergoes through a signal transduction pathway
distinct from the Fas-mediated one in murine cells [9]. In this
communication, we have examined inhibitory e¡ects of the
PK inhibitors on the Nef-induced and Fas-mediated apopto-
ses of uninfected human blood cells and discussed the feasi-
bility of clinical use of the drugs to prevent the development
of AIDS.
2. Materials and methods
2.1. Reagents and antibodies
Recombinant soluble Nef proteins of the IIIB and ELI strains of
HIV-1 were from Intracel, Cambridge, USA and Immuno Diagnos-
tics, Inc., New York, USA, respectively. A serine/threonine PK inhib-
itor, fasudil hydrochloride (hexahydro-1-[5-isoquinolinesulfonyl]-1H-
1,4-diazepine hydrochloride) and its metabolite M3 (1-[1-hydroxy-5-
isoquinolinesulfonyl]-homopiperazine) [10] were from Asahi Chemical
Industry Co. Ltd., Japan. H-7 (1-[5-isoquinolinylsulfonyl]-2-methylpi-
perazine) was from Sigma Chemical Co., USA. IL-1L converting en-
zyme (ICE) inhibitor I (acetyl-Try-Val-Ala-Asp-CHO) was from Cal-
biochem, La Jolla, USA. Mouse monoclonal antibodies (mAbs) to the
N-terminus of Nef protein (BRU strain) and to human CD95 (Fas)
(CH-11) were from Advanced Biotechnologies, Inc., Columbia, USA,
and Medical and Biochemical Laboratories, Co., Ltd. Japan, respec-
tively. Mouse mAbs against human CD25 and CD38 were from Phar-
Mingen, San Diego, USA.
2.2. Cells
Human CD4 T cell lines derived from lymphoma (H9), lympho-
blastoma (CEM-5) and T cell leukemia (Jurkat); CD4 CD8 T cell
line from lymphosarcoma (Tall-1); CD8 T cell line from normal
peripheral blood (5B5); B cell line from Burkitt lymphoma (Ramos);
monocyte line from histiocytic lymphoma (U937); and neutrophil
lines from myelogenous leukemia (K562) and promyelocytic leukemia
(HL60) were used as described previously [8]. Peripheral blood mono-
nuclear cells (PBMC) from healthy adults were incubated for 2 to 4
days in RPMI-1640 medium supplemented with 10% fetal calf serum
(FCS) in the presence of 1 Wg/ml phytohemagglutinin (PHA).
2.3. Assay of Nef protein bound to cell surfaces
Cell suspension was incubated with 1 Wg/ml Nef protein for 40 min
at 4‡C. After washing with phosphate bu¡ered saline (pH 7.2, PBS),
cells were stained with anti-Nef mAb and FITC-labeled secondary
Ab, and analyzed for the amount of Nef bound to the cell surfaces
by £owcytometry [8]. To analyze the e¡ect of PK inhibitors on the cell
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surface expression of a putative Nef-binding protein, PBMC were
activated with 1 Wg/ml PHA for 2 days at 37‡C in the presence of
various concentrations of PK inhibitors [9]. Cell line cells were like-
wise preincubated with the drugs for various periods. The cells were
washed with PBS and subjected to the Nef-binding assay as above.
2.4. Analysis of apoptotic cytolysis induced by Nef protein and
anti-CD95 (Fas) mAb
The procedure described previously [8] was used with slight mod-
i¢cation. Brie£y, cell suspension (105 cells in 100 Wl RPMI-1640 me-
dium with 10% FCS) was incubated either with 100 ng/100 Wl Nef
protein for 2 h on ice, anti-Nef mAb for 30 min on ice and then in a
96-well plate coated with anti-mouse IgG Ab for 2 days at 37‡C, or
with 1 Wg/ml anti-human CD95 (Fas) mAb for 6 h at 37‡C. The cells
were treated with the lysis solution (0.1% Triton X-100 and 50 Wg/ml
propidium iodite in 0.1% sodium citrate) and the nuclear fraction was
analyzed for DNA fragmentation by £owcytometry.
2.5. Inhibition of Nef-induced and Fas-mediated apoptoses by PK and
ICE inhibitors
PBMC activated with PHA and cell line cells were preincubated
with various concentrations of PK inhibitors or ICE inhibitor I for
various periods at 37‡C. The cells were then assayed for Nef-induced
apoptosis and Fas-mediated apoptosis as described above in the pres-
ence of each drug.
3. Results
3.1. Inhibitory e¡ect of ICE inhibitor on Nef-induced
apoptosis of human blood cells
Since Fas-mediated apoptosis has been shown to be inhib-
ited by ICE inhibitors, ICE inhibitor I was examined for in-
hibitory e¡ect on the Nef-induced apoptosis. The ICE inhib-
itor suppressed Fas-mediated apoptosis of human blood cells
caused by anti-Fas mAb, which occurred with restricted cell
types expressing Fas (CEM-5, H9, Jurkat and PHA-activated
PBMC), as reported previously [11] (Table 1). Apoptotic cy-
tolysis induced by the Nef protein of HIV-1 (IIIB strain),
which occurred with a broader spectrum of cell types than
those for Fas-mediated apoptosis [8], was also inhibited by
the ICE inhibitor (Fig. 1, Table 1). Similar results were ob-
tained for the Nef of HIV-1 ELI strain (data not shown).
3.2. Inhibition of Nef-induced apoptosis of human blood cells
by PK inhibitors
Since Nef-induced apoptosis of murine lymphoid cells is
suppressed by serine/threonine PK inhibitors [9], we examined
the e¡ect of the drugs on the apoptosis of human blood cells.
Whereas PK inhibitors, H-7, fasudil hydrochloride and its
active form metabolite M3, did not inhibit the Fas-mediated
apoptosis, these drugs strongly inhibited the Nef-induced
apoptosis of all cell lines tested and PHA-activated PBMC
(Fig. 1, Table 1). Essentially identical results were obtained
for the Nef protein of IIIB and ELI strains of HIV-1. The PK
inhibitors did not a¡ect the Nef-binding capacity of the cell
line cells and activated PBMC. Treatment of the soluble Nef
protein with the drugs a¡ected neither the cell surface-binding
activity nor the apoptosis-inducing activity of Nef (data not
shown). Fasudil hydrochloride and M3 inhibited the Nef-in-
duced apoptosis in a dose-dependent manner, in parallel with
the inhibitory e¡ect on PKC enzyme activity in vitro [12],
showing a complete inhibition at 1 to 10 WM (Fig. 2) and
no cytotoxicity at least at 30 WM for all cell types tested
(data not shown). On the other hand, H-7 suppressed cell
proliferation to some extent at 1 WM, a concentration inhibit-
ing the Nef-induced apoptosis.
Pretreatment of target cells with the PK inhibitors before
incubation with the Nef protein in the presence of each inhib-
itor was required for the inhibition of Nef-induced apoptosis.
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Fig. 1. E¡ect of inhibitors on the Nef-induced apoptotic cytolysis of
Jurkat cells. Cell suspension (105 cells in 100 Wl RPMI-1640 medium
with 10% FCS) was pretreated with inhibitors for 30 min at 37‡C,
then incubated with HIV-1 Nef protein (IIIB strain, 100 ng/100 Wl)
in the presence of drugs for 48 h at 37‡C, and analyzed for DNA
fragmentation by £owcytometry. a: Control, without Nef and drugs.
b: Nef without drugs. c: Nef and 1 WM fasudil hydrochloride. d:
Nef and 1 WM M3. e: Nef and 1 WM H-7. f: Nef and 1 mM ICE
inhibitor I.
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The inhibitory e¡ect depended on both the preincubation pe-
riod and concentration of the drugs. Preincubation of cell line
cells for more than 30 min and of PBMC for more than 60
min, respectively, was needed for e⁄cient inhibition by M3 at
1 WM, while a higher concentration and a longer preincuba-
tion period were required for fasudil hydrochloride (Fig. 3).
3.3. Inhibition of cell surface expression of a putative Nef
receptor in PBMC by PK inhibitors
The Nef protein, at the C-terminal domain, binds to cell
surfaces of various human blood cell line cells, which are
more or less activated [6^8]. Although Nef does not bind to
PBMC in a resting stage, stimulation with PHA confers the
Nef-binding capacity on a part of the cells [8]. These ¢ndings
suggest the presence of a putative Nef-binding protein (recep-
tor) responsible for the Nef-induced apoptosis and that cell
surface expression of the receptor molecule depends on cellu-
lar activation [6^8]. Although the PK inhibitors did not inter-
fere with the Nef binding to activated cells as described above,
a possibility remained that the drugs suppressed cell surface
expression of the putative Nef receptor. Incubation of cell line
cells with the PK inhibitors for 2 days a¡ected neither the
Nef-binding capacity nor cell surface markers of cellular acti-
vation, CD25 and CD38 (data not shown). On the other
hand, cell surface expression of the Nef-binding capacity of
PBMC, which was induced by incubation of the resting cells
with PHA for 2 days, was completely inhibited by fasudil
hydrochloride and M3 at 10 WM (Fig. 4) and thereby, the
PBMC remained insusceptible to the Nef-binding and Nef-
induced apoptosis. However, the treatment with the PK in-
hibitors did not in£uence the expression of CD25 and CD38,
cell surface markers of cellular activation (data not shown).
4. Discussion
Extensive destruction of a variety of uninfected blood cells
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Fig. 2. Dose-dependent inhibitory e¡ects of fasudil hydrochloride (a) and M3 (b) on the Nef-induced apoptotic cytolysis of cell line cells. The
procedure described in the legend for Fig. 1 was followed using PK inhibitors at indicated concentrations. (a) H9, (O) Jurkat, (E) Ramos, (b)
U937, and (R) K562 cells.
Fig. 3. E¡ects of preincubation period and concentration of PK inhibitors on inhibition of the Nef-induced apoptosis of PBMC. PBMC from
healthy adult were activated with 1 Wg/ml PHA for 2 days. The cells were then subcultured with various concentrations of fasudil hydrochloride
(a) and M3 (b) for indicated periods before subjected to the assay of Nef-induced apoptosis in the presence of each drug as described in the
legend for Fig. 1. Concentrations of the PK inhibitors were 0.1 WM (O), 0.3 WM (R), 1 WM (a), 3 WM (b), and 10 WM (E).
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during the subclinical stage of HIV-1 infection is likely re-
sponsible for the development of AIDS [1^4]. Tat and
gp120 of HIV-1, which induce Fas-dependent apoptosis of
restricted cell types [13], may contribute in part to the deple-
tion of uninfected cells. On the other hand, we have postu-
lated the involvement of Nef-induced apoptosis in this event
[6^8] and searched for drugs inhibiting the cell death [9]. The
present study demonstrated that the Nef-induced apoptotic
cytolysis of a broad spectrum of human blood cells was e⁄-
ciently inhibited by serine/threonine PK inhibitors, H-7, fasu-
dil hydrochloride and its metabolite M3, which did not inhibit
Fas-mediated apoptosis. These results appeared quite similar
to those obtained for murine lymphoid cells [9]. The Nef-in-
duced apoptosis, occurring with various cell types irrespective
of the presence of Fas [8], was also inhibited by ICE inhibitor
I, which a¡ects the lower stream of the Fas-mediated apop-
totic pathway [11]. These results suggest that although the
upper stream of signal transduction pathway of the Nef-in-
duced apoptosis is di¡erent from that of the Fas-mediated
one, they meet each other upstream of ICE into a common
track leading to apoptosis. Since the PK inhibitors did not
a¡ect the binding of Nef to cell surfaces, the drugs likely
inhibited phosphorylation of cellular protein(s) involved in
the a¥uent stream of the Nef-speci¢c pathway.
Pretreatment of the cells with the PK inhibitors was re-
quired for the inhibition, suggesting that once after the apop-
tosis-inducing signal is transduced by phosphorylation of the
protein(s), the PK inhibitors can no longer block the signal. A
longer preincubation period for fasudil hydrochloride was re-
quired than for M3, probably because fasudil hydrochloride
taken up by cells was converted to an active form M3 during
this period [10], and thereby impeded transduction of the
apoptosis-inducing signal introduced by binding of Nef to a
putative Nef receptor, a death-signalling receptor. The present
results strongly suggest that the Nef protein serves as a ligand
to such a putative Nef receptor, which may represent a mem-
ber of the tumor necrosis factor (TNF) receptor family [14].
Considering biological nature and spectrum of the Nef-in-
duced apoptosis [6^9], TNF-related apoptosis-inducing ligand
(TRAIL, Apo-2L) receptor [15^17] could be a most likely
candidate. Molecular characterization of the Nef-induced
apoptotic pathway is in progress.
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Table 1
Inhibitory e¡ects of drugs on Nef-induced and Fas-mediated apoptoses





















CEM-5 CD4 T 93 6 18 16 23 22 27 31 21 1
H9 CD4 T 92 9 11 7 7 86 91 79 83 7
Jurkat CD4 T 87 4 1 4 1 70 73 72 67 1
Tall-1 CD4 CD8 T 74 4 9 1 2 1 ^ ^ ^ ^
5B5 CD8 T 73 13 17 18 15 23 n.t.c n.t. n.t. n.t.
Ramos Blymphocyte 92 6 12 23 21 3 ^ ^ ^ ^
K562 Neutrophil 77 8 17 27 30 1 ^ ^ ^ ^
HL60 Neutrophil 83 9 23 21 17 3 ^ ^ ^ ^
U937 Macrophage 95 11 18 19 30 8 ^ ^ ^ ^
PBMC Normal 6 5 ^ ^ ^ ^ 2 ^ ^ ^ ^
PBMC PHA activatedd 64 7 8 7 7 37 40 35 37 7
aCells (105 cells/100 Wl) were incubated with 100 ng Nef (IIIB strain) and anti-Nef mAb for 48 h at 37‡C.
bCells (105 cells/100 Wl) were incubated with 100 ng mAb CH-11 for 6 h at 37‡C.
cNot tested.
dCells were activated with 1 Wg/ml PHA for 2 or 4 days for assay of Nef-induced or Fas-mediated apoptosis, respectively.
Fig. 4. Inhibitory e¡ect of PK inhibitors on cell surface expression of Nef-binding capacity of PBMC. PBMC were activated with 1 Wg/ml
PHA for 2 days in the presence of PK inhibitors. The cells were then treated with 1 Wg/ml Nef protein (IIIB strain) for 40 min at 4‡C, stained
with anti-Nef mAb and FITC-conjugated secondary Ab and assayed for the amount of Nef by £owcytometry. Bold lines, without anti-Nef
mAb; thin lines, with anti-Nef mAb. Control cells before PHA treatment (a). PHA-activated cells in the presence of no inhibitor (b), 1 WM
M3 (c), 10 WM M3 (e), 1 WM fasudil hydrochloride (d) or 10 WM fasudil hydrochloride (f).
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In addition, treatment of PBMC, and not cell line cells,
with the PK inhibitors suppressed cell surface expression of
the Nef-binding capacity, which is associated with cellular
activation and is a prerequisite for the Nef-induced apoptosis
[8], without a¡ecting cell surface markers of cellular activa-
tion. These results suggest that cell surface expression of the
putative Nef receptor also depends on phosphorylation of a
cellular protein which is speci¢cally inhibited by the PK in-
hibitors. Cell line cells, on the other hand, may have escaped
such regulatory mechanism. PBMC of HIV-1-infected patients
would be activated by cytokines induced by HIV-1 and other
opportunistic infections. Therefore, selective inhibition of the
cell surface expression of the Nef receptor by the PK inhib-
itors might also prevent the Nef-induced cytolysis of activated
cells.
Fasudil hydrochloride and M3 speci¢cally and e⁄ciently
inhibited the Nef-induced apoptotic cytolysis, which occurs
with a broader spectrum of cell types than those for Fas-
mediated apoptosis [8], and showed no cytotoxicity. Fasudil
hydrochloride has already been used as a therapeutic of sub-
arachnoidal hemorrhage to inhibit contraction of blood ves-
sels in the brain [18]. The present results taken together sug-
gest the feasibility of clinical use of the PK inhibitors to
prevent or delay the development of AIDS by inhibiting the
Nef-induced cytolysis of a broad spectrum of uninfected and
activated blood cells, in addition to suppressing TNF-induced
replication of the HIV-1 genome in infected cells [19].
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